AI in Pharma: The New Playbook for Drug Research & Development
In this webinar, our expert breaks down AI’s impact across the entire R&D pipeline – from discovery to FDA approval.
In this webinar, our expert breaks down AI’s impact across the entire R&D pipeline – from discovery to FDA approval.
AI will be the driving force behind tech M&A deals in 2025. From AI agent consolidation to big tech’s next battlefield, we highlight 7 areas where we expect to see deals this year.
From deal activity to top investors, we analyze the shifting landscape for AI in clinical trials to determine how the tech is transforming drug development for the better.
From clinical operations to drug development, we mapped 85+ startups bringing generative AI to the healthcare and life sciences industries.
From AI’s ascendance to cautious dealmaking, we break down the trends reshaping digital health in 2024 using CB Insights data.
AI promises to accelerate the path from bench to bedside. Using CB Insights data, we highlight emerging markets in the preclinical phase that are ripe for pharma investments and partnerships.
We analyze funding and acquisitions data, clinical progress, and partnership strategies to help pharma companies and investors navigate the maturing AI landscape in drug discovery.
We mined Roche’s acquisitions, investments, and partnerships to discern the company's strategic priorities. Here’s what pharma and diagnostics companies need to pay attention to.
The future of LLMs. Caregiving humanoid robots. Crypto’s baby steps. We use CB Insights data to uncover 15 emerging trends that will shape the tech landscape for years to come.
We analyzed Eli Lilly’s tech-focused acquisitions, investments, and partnerships to discern the company’s strategic priorities.
This report uses the CB Insights TECH Framework to rank clinical trials markets based on current commercial readiness and momentum.
From rapid, on-site diagnostics to novel stem cell therapies, animal health is seeing a wave of innovations to prevent, diagnose, and treat disease.
Bet on the right digital health markets. Dig into your rivals’ health tech strategies. Identify the best digital health startups.
In 2024 so far, Andreessen Horowitz’s leading AI priorities are multimedia generation and AI-fueled agents & copilots.
From protocol design to real-world data, we map the 96 tech companies making clinical trials faster, cheaper, and more patient-centric.
From medical scribes to clinical trial platforms, AI-driven solutions are key targets of digital health M&A deals in 2024 so far. Here’s where we’re seeing the most activity.
As concerns mount around the rise of counterfeit drugs, supply chain technologies such as IoT asset tracking, blockchain ledgers, and product & packaging authentication can provide pharma companies with more visibility and supply chain security.
We mined Sanofi's investments and partnerships to discern the company’s strategic priorities.
Tech leaders are aggressively applying cloud computing and generative AI to tackle issues in healthcare. We look at how 4 tech giants are building their positions in the industry using strategic investments, partnerships, and product launches.
From commercializing quantum computer applications in industries like finance and healthcare to defending against quantum algorithms with new post-quantum cryptography standards, the quantum information landscape is rapidly becoming more complex. We break down the tech companies defining the quantum future.
We mined earnings calls, analyzed business relationships, and dug into investments and acquisitions to survey the AI activities of some of the world’s largest companies across industries.
We mined Google’s investments and partnerships to discern the company's strategic priorities in healthcare.
We mined Microsoft's acquisitions, investments, and partnerships to discern the company's strategic priorities in healthcare.
We mined AstraZeneca’s partnerships, investments, and acquisitions to discern the company's strategic priorities.
From simulating protocol variations for trial design to predicting relapse rates in patients, we take a look at how AI-powered simulations are improving clinical trial efficiency and success.
Pharma giant Bristol Myers Squibb's 3 mega-acquisitions cap off a year of heightened big pharma M&A activity.